Technical Analysis for CTLT - Catalent, Inc.
|Grade||Last Price||% Change||Price Change|
CTLT closed up 1.14 percent on Friday, January 18, 2019, on 48 percent of normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
Earnings due: Feb 4
|See historical CTLT trend table...|
|Date||Alert Name||Type||% Chg|
|Jan 18||Crossed Above 50 DMA||Bullish||0.00%|
|Jan 18||Overbought Stochastic||Strength||0.00%|
|Jan 18||Up 3 Days in a Row||Strength||0.00%|
|Jan 18||Up 4 Days in a Row||Strength||0.00%|
|Jan 18||Upper Bollinger Band Touch||Strength||0.00%|
|Jan 17||Non-ADX 1,2,3,4 Bearish||Bearish Swing Setup||1.14%|
|Jan 17||Pocket Pivot||Bullish Swing Setup||1.14%|
|Jan 17||Weak + Overbought||Other||1.14%|
|Jan 17||Overbought Stochastic||Strength||1.14%|
|Jan 17||Up 3 Days in a Row||Strength||1.14%|
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicatorsBasic chart:
Catalent, Inc. provides advanced delivery technologies and development solutions for drugs, biologics, and consumer health products. It operates through Oral Technologies, Medication Delivery Solutions, and Development & Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development, and manufacturing of oral dose forms for prescription and consumer health products. This segment's oral dose forms include softgel, modified release technologies, and immediate release solid oral products. The Medication Delivery Solutions segment offers formulation, development, and manufacturing services for delivery of drugs and biologics administered through injection, inhalation, and ophthalmic routes. The Development and Clinical Services segment provides manufacturing, packaging, storage, and inventory management services for drugs and biologics in clinical trials. This segment also offers analytical chemical and cell-based testing and scientific services, stability testing, respiratory products formulation and manufacturing, regulatory consulting, and bioanalytical testing for biologic products. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
|Indicator||Bull Case||Neutral / Hold||Bear Case|
|Oversold / Overbought|
|Summary:||Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.|
See more CTLT news...
|52 Week High||47.87|
|52 Week Low||29.23|
|200-Day Moving Average||39.9477|
|50-Day Moving Average||35.3716|
|20-Day Moving Average||32.2995|
|10-Day Moving Average||33.891|
|Average True Range||1.0635|
|Chandelier Exit (Long, 3 ATRs )||32.7595|
|Chandelier Exit (Short, 3 ATRs )||32.4205|
|Upper Bollinger Band||35.8542|
|Lower Bollinger Band||28.7448|
|Percent B (%b)||0.97|
|MACD Signal Line||-0.7281|
|Market Cap||4.46 Billion|
|Num Shares||125 Million|
|Price-to-Earnings (P/E) Ratio||40.93|
|Pivot Point Level||Traditional / Classic||Fibonacci||Demark||Woodie||Camarilla|
|Resistance 4 (R4)||36.97|
|Resistance 3 (R3)||36.93||36.44||36.74|
|Resistance 2 (R2)||36.44||36.09||36.46||36.67|
|Resistance 1 (R1)||36.03||35.88||36.23||36.06||36.59|
|Support 1 (S1)||35.12||35.19||35.33||35.16||34.63|
|Support 2 (S2)||34.63||34.98||34.65||34.55|
|Support 3 (S3)||34.22||34.63||34.48|
|Support 4 (S4)||34.25|